Amit Bhatt

Freedman, S., Hercinovic, A., Wallace, D. K., Kraker, R., Li, Z., Bhatt, A., et al. (2022). Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. Ophthalmology, 129(10), 1120-1128. 10.1016/j.ophtha.2022.05.019 (Original work published 2022)

Wallace, D. K., Hercinovic, A., Freedman, S., Crouch, E., Bhatt, A., Hartnett, E., et al. (2023). Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity. Journal Of The American Association For Pediatric Ophthalmology And Strabismus, 27(1), 10.e1-10.e8. 10.1016/j.jaapos.2022.11.020 (Original work published 2023)

Wallace, D. K., Kraker, R., Freedman, S., Crouch, E., Bhatt, A., Hartnett, E., et al. (2020). Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. Jama Ophthalmology, 138(6), 698-701. 10.1001/jamaophthalmol.2020.0334 (Original work published 2020)

Wallace, D. K., Kraker, R., Freedman, S., Crouch, E., Hutchinson, A., Bhatt, A., et al. (2017). Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. Jama Ophthalmology, 135(6), 654-656. 10.1001/jamaophthalmol.2017.1055 (Original work published 2017)